Report Highlights
The global market for DNA read, write and edit applications should grow from $17.0 billion in 2019 to $43.1 billion by 2024 with a compound annual growth rate (CAGR) of 20.5% during the period of 2019-2024.
Report Includes
- 28 data tables and 77 additional tables
- An overview of the global market for DNA read, write and edit technologies, applications, and industries
- Analyses of global market trends, with market data from 2017, 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Discussion on sequencing technologies, market applications, industry structure, and important clinical sequencing initiatives
- Information pertaining to several significant large-scale research initiatives that are contributing to sequencing services, write synthesis and gene editing technologies’ market development
- A look at the innovations in pharmaceutical and biotechnology companies and research & development programs in stem cell-based therapies and gene therapies
- Coverage of significant patents and their allotments in each category, as well as major industry acquisitions and strategic alliances data
- Company profiles of over 320 major global players within the industry, including 3Billion Inc., 23Andme Inc., Bayer AG, Becton, Dickinson and Co. (BD), Bio-Rad Laboratories, Pacific Biosciences, Qiagen NV, Roche Holding AG and Thermo Fisher Scientific Inc.
Report Scope
The scope of the report includes DNA read, write and edit technologies, applications, industries, initiatives, patents and companies. The markets for read, write and edit products and services are given for 2017, 2018, 2019 (estimated) and 2024 (forecast).
This report reviews the main read, write and edit technologies and explains why genetic variation is important in clinical testing and disease. It then discusses significant large-scale research initiatives that impact read, write and edit applications. Of particular interest is a discussion of population-scale sequencing projects throughout the world, and their likely impact. The main market driving forces for read, write and edit products and services are listed and discussed.
The report quantifies each of the main market segments. The read (sequencing) market is quantified by delivered format, including sequencing workflow products (sample preparation kits and reagents, sequencing instruments and consumables, and informatics) and sequencing services (clinical diagnostics and sequencing services to applied market customers).
The sequencing workflow products market is quantified by type, that is, DNA isolation and extraction; target enrichment; library preparation; and informatics/ecosystems. The sequencing instruments and consumables market is given by platform (Sanger, NGS and 3GS).
The sequencing services market is analyzed by end user application (applied, clinical, and R&D). Within sequencing services, the applied market is analyzed by end-user application (agriculture, biopharma, consumer, microbiology, population-scale genomics, synthetic biology and other).
Also within sequencing services, the clinical market is analyzed and quantified by disease category (cardiovascular, clinical microbiology and infectious diseases, Mendelian disorders, metabolic/immune disorders, neurology, oncology, reproductive health and transplant medicine).
The DNA write (synthesis) market is quantified by product type (oligonucleotides, synthetic biology parts, genes and RNA therapeutics). The oligonucleotide market is analyzed by application (gene editing, sequencing, PCR, FISH, microarray, gene synthesis and other). The gene market is quantified by gene type (standardized, value-added). Finally, the RNA therapeutics market is quantified by platform (RNA interference, antisense oligos, micro RNA modulation and mRNA) and by disease category (cancer, hematology, musculoskeletal, neurology and rare diseases).
The DNA edit (gene editing) market is quantified by application (agriculture, biopharma, diagnostics and therapeutics); editing platform (CRISPR, meganuclease, TALEN, ZFN). The gene editing agriculture market is analyzed by product type (crop/seeds, livestock). The gene editing biotechnology market is analyzed by product type (kits and reagents, cell line engineering, animal models and services). The gene editing therapeutics market is analyzed by disease category (eye and rare diseases).
Specific geographic markets discussed include North America, Europe, Asia-Pacific, and the rest of the world (ROW).
Industry sectors analyzed include next-generation sequencing; long read sequencing; DNA synthesis; RNA therapies; and gene editing.
More than 320 companies in the read, write and edit industry are profiled in this report.
BCC Research also provides a summary of more than 180 of the main industry acquisitions and strategic alliances that took place from January 2018 through June 2019, including key alliance trends.
Analyst Credentials
John Bergin has produced successful and highly regarded market research reports in the life science industry for BCC research for more than 10 years. Mr. Bergin has held business development and international sales and marketing positions with Corning Inc., an advanced materials company. He has also held executive management positions with IBC Advanced Technologies, a molecular recognition company specializing in separations. Mr. Bergin's extensive expertise in commercializing new technologies is reflected in his market research reports.
Mr. Bergin received a BS degree in Chemistry and Masters of Business Administration (MBA) degree from Brigham Young University and an MS degree in biotechnology from Johns Hopkins University. John Bergin is a pseudonym of the author.
Related Reports
Direct-to-Consumer Genetic Testing: Global Markets and Technologies
The global market for DTC genetic testing is expected to grow from $2.3 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.0% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Synthetic Biology: Global Markets
The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.
Recent Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Commercial Amino Acids
The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Top Trending Reports
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Medical Devices: Technologies and Global Markets
The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More